Figure 2. Survival analysis of DUXAP8 and DUXAP9 in chRCC (chromophobe renal cell carcinoma) and pRCC (papillary renal cell carcinoma). (A) Prognostic value (overall survival) of DUXAP8 in chRCC; (B) prognostic value (disease free survival) of DUXAP8 in chRCC; (C) prognostic value (overall survival) of DUXAP8 in pRCC; (D) prognostic value (disease free survival) of DUXAP8 in pRCC; (E) prognostic value (overall survival) of DUXAP9 in chRCC; (F) prognostic value (disease free survival) of DUXAP9 in chRCC; (G) prognostic value (overall survival) of DUXAP9 in pRCC; (H) prognostic value (disease free survival) of DUXAP9 in pRCCs.